Impact investing: the blood test that could screen early-stage cancers
array(4) { [0]=> string(8) "Advisers" [1]=> string(11) "Individuals" [2]=> string(13) "Institutional" [3]=> string(12) "Shareholders" }
Regnan’s impact investment team believes ‘liquid biopsy’ technology could grow into a $US20 billion to $100 billion market. Regnan analyst Maxine Wille explains Blood tests could diagnose cancer and disease…